Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

"Once in your life, we should try." Peter Lau's simple seven-word mantra has guided the world's most accomplished racehorse ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.

Recent changes to the legal process in Alabama makes it more difficult to challenge such cases, the report states.

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

The return on equity and its more expansive variant is what a company makes on the capital it has invested in business, and is a measure of business quality. Click to read.

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

Researchers at Penn Medicine conducted a pilot randomized controlled trial to test the hypothesis that an e-triage ...